Pharmacy Website
    Clinic Website

    Intelligence » COPD » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    Targeted Lung Denervation procedure significantly reduces COPD problems

    Tuesday, September 18, 2018 -- First results from a clinical trial of a procedure to open obstructed airways in patients with chronic obstructive pulmonary disease have shown that it significantly reduces problems associated with the disease and is safe.

    AZ to file triple combination therapy for COPD

    Monday, September 17, 2018 -- AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).

    Revefenacin Cuts COPD Exacerbation Rates in Phase 3 Studies

    Tuesday, September 18, 2018 -- Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.

    AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data

    Tuesday, September 18, 2018 -- AstraZeneca struck out in May in trying to expand severe eosinophilic asthma drug Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.

    Triple Tx Effective in COPD with Low Exacerbation Risk

    Monday, September 17, 2018 -- (MedPage Today) -- And models show exacerbations further decreasing

    PDE3/4 Inhibitor Yields Symptom Relief in COPD

    Tuesday, September 18, 2018 -- (MedPage Today) -- Tested as standalone, but potential role seen as add-on therapy

    Lung Denervation Cuts COPD-Related Events, Admissions

    Wednesday, September 19, 2018 -- (MedPage Today) -- One-time therapy showed most benefit in highly symptomatic patients

    [Articles] Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

    Sunday, September 16, 2018 -- BGF MDI was efficacious, well tolerated, and could be a more appropriate treatment than the corresponding dual therapies for symptomatic patients with moderate to very severe COPD, irrespective of exacerbation history.